Vesna Višekruna Vučina
A5072060972- Respiratory viral infections research
- Influenza Virus Research Studies
- Vaccine Coverage and Hesitancy
- SARS-CoV-2 and COVID-19 Research
- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- Hepatitis Viruses Studies and Epidemiology
- Immune responses and vaccinations
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Misinformation and Its Impacts
- Viral Infections and Vectors
- COVID-19 Clinical Research Studies
- Mosquito-borne diseases and control
- Dengue and Mosquito Control Research
- Respiratory Support and Mechanisms
- Pneumocystis jirovecii pneumonia detection and treatment
- Migration and Labor Dynamics
- Migration, Health and Trauma
- Healthcare Systems and Public Health
Hrvatski zavod za javno zdravstvo
2013-2024
Institut za filozofiju
2021
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
Invasive meningococcal disease (IMD) is a major cause of bacterial meningitis and septicaemia although infection by some serogroups may be prevented through vaccination. We aimed to describe the epidemiology IMD in EU/EEA countries during 2004-2014 monitor serogroup- age-specific trends, compare country trends period C conjugate (MCC) vaccine introduction.We analysed surveillance data age, gender, serogroup, outcome. estimated percentage change annual notification rate (NR), using linear...
Abstract Background Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test‐negative study. Materials Methods Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since...
Abstract Background In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure vaccine effectiveness (VE). Methods Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic...
Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 VE age genetic subgroups to explore cohort. Methods We measured against (sub)clades. stratified usual groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of (I-REV) hypothesis,...
In recent years various EU/EEA countries have experienced an influx of migrants from low and middle-income countries. 2018, the "Vaccine European New Integrated Collaboration Effort (VENICE)" survey group conducted a among 30 to investigate immunisation policies practices targeting irregular migrants, refugees asylum seekers (later called "migrants" in this report). Twenty-nine participated survey. Twenty-eight reported having national children/adolescent adult however vaccinations offered...
We conducted a multicentre test-negative case-control study in 27 hospitals of 11 European countries to measure 2015/16 influenza vaccine effectiveness (IVE) against hospitalised A(H1N1)pdm09 and B among people aged ≥ 65 years. Patients swabbed within 7 days after onset symptoms compatible with severe acute respiratory infection were included. Information on demographics, vaccination underlying conditions was collected. Using logistic regression, we measured IVE adjusted for potential...
Background During the 2015/16 influenza season in Europe, cocirculating viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from B/Yamagata component trivalent vaccine. Methods We used test‐negative design a multicentre case‐control study twelve European countries to measure vaccine effectiveness ( VE ) against medically attended influenza‐like illness ILI laboratory‐confirmed as influenza. General practitioners swabbed systematic sample of consulting patients random...
Understanding the country-specific epidemiology of disease, which may vary greatly among countries, is crucial for identifying most appropriate preventive and control measures. An overview local viral hepatitis in Croatia given this paper. The overall prevalence B low (less than 2% HBsAg carriers general population). Hepatitis incidence began to decline significantly following introduction universal vaccination 1999. Information on seroprevalence derived from routine testing certain...
Influenza A(H3N2) viruses predominated in Europe 2016-17. In 2017-18 and A(H1N1)pdm09 co-circulated. The vaccine component was the same both seasons; while changed 2017-18. seasons, seed developed adaptations/alterations during propagation eggs, impacting antigenicity.
<title>Abstract</title> <bold>Background</bold> The Influenza – Monitoring Vaccine Effectiveness (I-MOVE/I-MOVE+) and the Effectiveness, Burden Impact Studies (VEBIS) hospital networks have conducted seasonal multicentre, test-negative, case–control studies in Europe to measure influenza vaccine effectiveness (IVE) against (sub)types since 2015/16. We aimed effect of chronic conditions on A subtype VE among older adults (≥65 years) using pooled-season data from 2015/16 2023/24....
In May 2018, measles was introduced in the Dubrovnik region by an adult who recently travelled to Kosovo*. Control measures and outbreak investigation were implemented: 15 epidemiologically-linked cases met case definition of a visitor/resident Dubrovnik-Neretva County with laboratory-confirmed symptom onset beginning on 19. New identified through hospitals primary care physicians. Throat swabs, urine and/or serum samples collected from cases. RT-PCR detection viral RNA IgM/IgG used confirm...
Influenza A(H3N2) viruses dominated early in the 2022–23 influenza season Europe, followed by higher circulation of A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated vaccine effectiveness (VE) using a multicentre test-negative study. Primary practitioners collected information specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, (sub)type clade, age group, target group time since vaccination, logistic regression....
Background: In 2021–22, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure vaccine effectiveness (VE). Methods: Primary practitioners collected information on patients presenting with acute respiratory infection. Cases were A(H3N2) or A(H1N1)pdm09 RT-PCR positive and controls virus negative. We calculated VE using logistic regression, adjusting for site, age, sex, onset date, presence of chronic conditions. Results:...
<h3>Goal</h3> The aim of the research was to determine influence various media, social and institutional sources information on attitudes about vaccination, i.e. belief in conspiracy theories field vaccination. So far, some studies, especially situations vaccine confidence crises, showed that official (public media state institutions) new information, such as Internet, have different effects when it comes vaccination attitudes. However, topic is largely unexplored. <h3>Methods</h3> conducted...